A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies

Experimental Eye Research
Yong LiChui Ming Gemmy Cheung

Abstract

Anti-vascular endothelial growth factor (VEGF) therapies lead to a major breakthrough in treatment of neovascular retinal diseases such as age-related macular degeneration or diabetic retinopathy. Current management of these conditions require regular and frequent intravitreal injections to prevent disease recurrence once the effect of the injected drug wears off. This has led to a pressing clinical need of developing sustained release formulations or therapies with longer duration. A major drawback in developing such therapies is that the currently available animal models show spontaneous regression of vascular leakage. They therefore not only fail to recapitulate retinal vascular disease in humans, but also prevent to discern if regression is due to prolonged therapeutic effect or simply reflects spontaneous healing. Here, we described the development of a novel rabbit model of persistent retinal neovascularization (PRNV). Retinal Müller glial are essential for maintaining the integrity of the blood-retinal barrier. Intravitreal injection of DL-alpha-aminoadipic acid (DL-AAA), a selective retinal glial (Müller) cell toxin, results in persistent vascular leakage for up to 48 weeks. We demonstrated that VEGF concentrations were...Continue Reading

Citations

Jul 31, 2019·Investigative Ophthalmology & Visual Science·Beiying QiuXiaomeng Wang
Feb 13, 2021·Molecular Therapy. Methods & Clinical Development·Thilo M BuckJan Wijnholds
Dec 5, 2020·Oxidative Medicine and Cellular Longevity·Xiaoqiang XiaoHaoyu Chen
Dec 22, 2021·Translational Vision Science & Technology·Wen-Chia HuangSung-En Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.